Biomarkers for Oligometastatic NSCLC
Author Information
Author(s): Mandy Jongbloed, Martina Bortolot, Leonard Wee, Jarno W.J. Huijs, Murillo Bellezzo, Rianne D.W. Vaes, Frank Aboubakar Nana, Koen J. Hartemink, Dirk K.M. de Ruysscher, Lizza E.L. Hendriks
Primary Institution: Maastricht University Medical Center+
Hypothesis
Can biomarkers identified in other stages of NSCLC be applied to oligometastatic disease?
Conclusion
Biomarkers for oligometastatic NSCLC are promising but still lack sufficient validation and clear definitions.
Supporting Evidence
- Biomarkers are needed to avoid futile treatments in patients with oligometastatic disease.
- Current biomarkers lack prospective validation in clinical trials.
- Liquid biopsies and imaging-based biomarkers are promising for future evaluation.
Takeaway
Doctors are trying to find special markers in cancer that can help them choose the best treatment for patients with a few cancer spots, but they need more research to be sure.
Methodology
Review of existing literature on biomarkers in oligometastatic NSCLC.
Potential Biases
Data may be biased due to heterogeneous patient populations.
Limitations
Current biomarkers are in early development stages and lack prospective validation.
Participant Demographics
Patients with oligometastatic NSCLC, primarily those with ≤3 extracranial metastases.
Statistical Information
P-Value
0.66
Confidence Interval
95% CI: 1.15–2.13
Statistical Significance
p=0.66
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website